Axogen appoints Kathy Weiler to its board, effective Dec 20, 2023

Axogen, Inc.

Board expanded to 10; Weiler serves on Governance, Nominating & Sustainability and Quality, Compliance & Portfolio committees.
Weiler is EVP, Chief Commercial & Growth Officer at Amwell (NYSE: AMWL); 20+ years in healthcare commercial leadership.
Initial stock option grant of $275k value vesting over 3 years; annual equity grants of $150k (half options, half RSUs) vesting 1 year.
Compensation includes quarterly cash retainer of $10,000 plus $1,250 per committee served.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kathy Weiler

Director

AXGN · Axogen, Inc.

Effective: 2023-12-20
Filed: December 26, 2023, 6:59 PM ET

On December 20, 2023, the board of directors (the “Board”) of Axogen, Inc. (the “Company”) increased the size of the Board from nine directors to ten directors, and appointed Kathy Weiler to fill the newly created vacancy effective December 20, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kathy Weiler was appointed as Director at Axogen, Inc..

Action: appointed
Role: Director

Exact text from the filing

On December 20, 2023, the board of directors (the “Board”) of Axogen, Inc. (the “Company”) increased the size of the Board from nine directors to ten directors, and appointed Kathy Weiler to fill the newly created vacancy effective December 20, 2023.

View on SEC.gov

Axogen, Inc. filing history →

Source: SEC EDGAR

accession 0000805928-23-000156

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.